Abstract 1571P
Background
In France, oncology is one of the disciplines for which the percentage of residents reorientating at the start of internship towards another specialty is the highest (8-10%). The determinants of this reorientation are unknown.
Methods
We conducted a quantitative online survey with the 121 interns of the 2022-2023 class during their 1st year of oncology training, with 2 follow-ups over 2 months. 36 potential determinants from previous works (Wright et al. 2004; Beaulieu et al. 2010) were evaluated using a 5-point Likert scale alongside parameters describing the resident. We also assessed their satisfaction with the teaching received. We conducted univariate and multivariate linear regression analyses.
Results
The response rate was 107/121 (88.5%), but 99 questionnaires were usable for the determinants analysis (81.2%). 9 residents were considering or may consider changing speciality. In multivariate analysis, 3 factors were associated with considering a change of specialty: “desire for social commitment” (β=2.15, p=.025), “other experience during the 2 nd -cycle hospital traineeships” (β=3.64, p<.001) and “interest in emergency care” (β=2.13, p=.028). Satisfaction with the education received was negatively associated with the desire to change specialty (β=-3.49, p<.001). The determinants of satisfaction in oncology training were: “being able to move to the desired university” (β=4.24, p=.016), “an image of dynamism of oncology” (β=4.68, p<.001); on the other hand, the “desire for short training” was negatively associated with satisfaction with oncology training (β=0.281, p=.042).
Conclusions
We identified 2 intrinsic factors (social commitment and interest in emergency care) and 2 extrinsic factors (other significant experiences during 2nd-cycles hospital traineeships and low satisfaction in oncology training) as being able to explain the wish of reorientation among oncology residents.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Centre Oscar Lambret.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1607P - Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 10
1608P - Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial
Presenter: Michael Hofman
Session: Poster session 10
1609P - PSMA-PET and PROMISE re-define stage and risk in patients with prostate cancer
Presenter: Wolfgang Fendler
Session: Poster session 10
1610P - Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig
Presenter: Andrew Armstrong
Session: Poster session 10
1611P - Haematologic impact of [177Lu]Lu-PSMA-617 versus ARPI change in patients with metastatic castration-resistant prostate cancer in PSMAfore
Presenter: Kim Nguyen Chi
Session: Poster session 10
1612P - Impact of FANCA, ATM, CDK12 alterations on survival in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: David Lorente
Session: Poster session 10
1613P - Clinically advanced prostate cancer (CAPC) featuring BRCA2 loss: A comprehensive genomic profiling (CGP) study
Presenter: Chiara Mercinelli
Session: Poster session 10
1614P - PSA responses and PSMA scan changes after immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT)
Presenter: Ravi Madan
Session: Poster session 10
1615P - A new prognostic model of overall survival (OS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC)
Presenter: Susan Halabi
Session: Poster session 10